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SUMMARY
Cell-based strategies represent a new frontier in the
treatment of immune-mediated disorders. However,
the paucity of markers for isolation of molecularly
defined immunomodulatory cell populations poses
a barrier to this field. Here, we show that ATP-bind-
ing cassette member B5 (ABCB5) identifies dermal
immunoregulatory cells (DIRCs) capable of exerting
therapeutic immunoregulatory functions through
engagement of programmed cell death 1 (PD-1). Pu-
rified Abcb5+ DIRCs suppressed T cell proliferation,
evaded immune rejection, homed to recipient im-
mune tissues, and induced Tregs in vivo. In fully ma-
jor-histocompatibility-complex-mismatched cardiac
allotransplantation models, allogeneic DIRCs signifi-
cantly prolonged allograft survival. Blockade of
DIRC-expressed PD-1 reversed the inhibitory effects
of DIRCs on T cell activation, inhibited DIRC-depen-
dent Treg induction, and attenuated DIRC-induced
prolongation of cardiac allograft survival, indicating
that DIRC immunoregulatory function is mediated,
at least in part, through PD-1. Our results identify
ABCB5+ DIRCs as a distinct immunoregulatory cell
population and suggest promising roles of this
expandable cell subset in cellular immunotherapy.
INTRODUCTION
Skin contains large numbers of effector T cells, particularly in the
dermis (Clark et al., 2006). Cutaneous immunity must therefore
be tightly regulated to prevent inappropriate immune activation,
while at the same time maintaining the ability to combat harmful
pathogens. While this control is in part accomplished by resident
tolerogenic immune cell populations, including Tregs (Dudda
et al., 2008), we hypothesized that skinmight additionally contain
non-hematopoietic lineage cell populations with immunoreg-
ulatory functions, with potential similarity to immunoregulatory
mesenchymal stem cells (MSCs) in other tissues (Uccelli et al.,
2008). We reasoned that this possibility, if correct, would then
provide for relatively easily accessible cell populations for use
in cell-based immunomodulatory strategies. We further hypoth-
esized that the stem cell marker (Ksander et al., 2014) ABCB5
might identify such cell populations in normal skin, given its
original discovery as a molecular determinant of skin-associated
tissue precursors (Frank et al., 2003; Schatton et al., 2008) and
immunoregulatory cell subsets in skin-associated malignancy
(Schatton et al., 2010).
RESULTS
Human Dermis Contains a Cell Population Marked by
ABCB5
We first characterized ABCB5 expression in healthy human
skin. Immunostaining revealed that ABCB5+ cell subsets reside
in the reticular dermis (Figure 1A) at frequencies ranging from
1.5% to 4.0% of dermal cells (2.5% ± 0.8%, mean ± SE, n = 3
donors, Figure 1B) and that this subpopulation is distinct from
CD34+ dermal dendritic cells, neighboring fibroblasts, or
CD31+ endothelial cells (Figure 1C). Flow cytometric analyses
confirmed negativity of ABCB5+ skin cells for CD34, a marker
of dermal dendritic cells and hematopoietic stem cells, and
CD31, a marker of endothelial lineage differentiation (Fig-
ure 1D). Furthermore, ABCB5+ skin cells exhibited negativity
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for the pan-hematopoietic lineage marker, CD45 (Figure 1D),
documenting absence of overlap with skin-resident immune
cell populations. While ABCB5+ skin cells preferentially co-
expressed the MSC markers CD29, CD44, CD49e, CD73,
CD105, and CD166 on >90% of cells, respectively, only distinct
subpopulations of cells with positivity for each MSC marker ex-
hibited positivity for ABCB5 (Figure 1D), demonstrating that
ABCB5 identifies a previously unrecognized and phenotypically
unique dermal cell subset.
ABCB5+ Skin Cells Preferentially Express the Immune
Checkpoint Receptor PD-1
Given the preferential association ofMSCmarker-positive (Frank
et al., 2005), ABCB5-expressing cell subsets in skin-associated
malignancy (Schatton et al., 2008) with immune checkpoint
molecules, including PD-1 (Schatton et al., 2010), we next
characterized the PD-1 pathway repertoire of ABCB5+ skin cells.
Immunofluorescence double staining of human skin sections
revealed preferential coexpression of ABCB5 with PD-1 and
demonstrated that this subpopulation is cytologically distinct
from CD45+ skin-associated lymphocytes (Figure 1E). Flow
cytometric analysis of single cell suspensions derived from
human skin biopsies (n = 4 donors) further confirmed PD-1
expression by CD45– human skin cells at relative frequencies
not significantly different from those observed in CD45+ lympho-
cytic skin infiltrates (Figure 1F, 16.0% ± 3.6% versus 15.3% ±
3.7%, mean ± SE, not significant [NS]). ABCB5+CD45– cells iso-
lated from human skin also demonstrated expression of PD-1
mRNA, as determined by RT-PCR amplification of the full coding
sequence (CDS) of the human PD-1 (PDCD1) gene (Figure 1G).
Moreover, quantitative real-time PCR revealed preferential
expression of PD-1 mRNA by purified ABCB5+ versus ABCB5–
skin cells (Figure 1H and 1.2 ± 0.2-fold versus 0.5 ± 0.1-fold
expression compared with detection in peripheral blood mono-
nuclear cells (PBMCs), mean ± SE, p < 0.05). Preferential PD-1
expression at the protein level by ABCB5+ compared to
ABCB5– skin cells was shown by triple-color flow cytometry of
single cell suspensions derived from human skin (Figure 1I,
90.9% ± 4.6% versus 9.1% ± 4.6% of CD45– skin cells, mean
± SE, p < 0.001). ABCB5+ subpopulations did not express the
costimulatory ligands PD-L1, PD-L2, B7.1 (CD80), or B7.2
(CD86) at significant levels (results not illustrated). Together,
these findings demonstrate preferential expression of the
immunologic checkpoint receptor, PD-1, by human ABCB5+
skin cells.
Murine Skin Contains Abcb5+ Dermal Cells that
Preferentially Express PD-1
In order to explore the immunoregulatory roles of this dermal
cell population in murine syngeneic and allogeneic in vivo
models, we characterized its presence and molecular pheno-
type also in murine skin. Immunofluorescence staining re-
vealed rare Abcb5+ cells residing in the dermis but not in the
epidermis or hair follicle (Figure 2A), consistent with findings
in human skin (Figure 1A). Flow cytometry of single cell suspen-
sions derived from murine (BALB/c) skin also revealed
preferential PD-1 expression by Abcb5+ compared to Abcb5–
skin cells (Figure 2B, 46.8% ± 7.6% versus 4.0% ± 0.7% of
CD45– skin cells, mean ± SE, p < 0.001), consistent with find-
ings in human skin (Figure 1I). Moreover, immunofluorescence
double staining of murine skin sections further confirmed pref-
erential coexpression of Abcb5 with PD-1 and showed that
murine skin contains PD-1+CD45– cells, in addition to PD-
1+CD45+ lymphocytes (Figure 2C). Additionally, in a side-by-
side human/mouse immunoenzymatic staining experiment
across the anastomosis of human skin to Rag2/ mouse xe-
nografts, using an anti-ABCB5 monoclonal antibody (mAb)
directed against a species-conserved extracellular epitope of
the molecule (Frank et al., 2003), we confirmed the exclusive
localization of human ABCB5+ and mouse Abcb5+ cell popula-
tions to the dermis (Figure 2D), with human ABCB5+ dermal
cells in anastomosing skin readily distinguishable from murine
Abcb5+ cell subsets by co-staining for human-specific major
histocompatibility complex (MHC) class I (Figure 2E). The inci-
dentally observed relative increase of ABCB5+ cell frequency at
the site of anastomosis (Figure 2D) suggests activation of this
cell population during the wound healing response. Next, we
developed a protocol for isolating, cloning, propagating, and
expanding murine Abcb5+ dermal cells in vitro, under defined
medium conditions already employed previously for the culture
of human ABCB5+ progenitor cells (Frank et al., 2003). Flow cy-
tometric analysis of clonally derived murine dermal cell cultures
revealed Abcb5 expression by the majority of cells in early
passages (Figure 2F). Further characterization with respect to
MSC antigens (Uccelli et al., 2008) demonstrated high expres-
sion of CD29, CD44, CD49e, CD73, CD105, and CD166 and
absence of significant levels of CD31, CD34, or CD45 expres-
sion (Figure 2F), consistent with findings in human ABCB5+
dermal cells (Figure 1D). Additionally, like human ABCB5+
dermal cells, murine Abcb5+ cells showed marked positivity
for the co-inhibitory receptor, PD-1, in early passages, as
determined by flow cytometry (Figure 2G) and RT-PCR ampli-
fication of the full CDS of the molecule (Figure 2H). While mu-
rine dermal cells exhibited increasingly lower PD-1 expression
during ex vivo culture, possibly due to absent functional re-
quirement or physiological stimuli, they nevertheless main-
tained a PD-1+ cell population (cell frequency 6.8% ± 0.8%,
mean ± SE) throughout later passages (Figure 2I).
Abcb5 Marks Dermal Immunoregulatory Cells that
Suppress Alloantigen- and Mitogen-Dependent
Immunity
To investigate the immunomodulatory capacity of Abcb5+
dermal immunoregulatory cells (DIRCs), we grafted 33 106 syn-
geneic C57BL/6-derived DIRCs or fully MHC-mismatched
BALB/c-derived DIRCs intravenously (i.v.) to C57BL/6 recipient
mice (Figure 3A). Seven days post injection, we harvested
the spleens of recipient mice and performed standard one-
way mixed lymphocyte reactions (MLRs) using irradiated naive
BALB/c or C3H/HeJ splenocytes as stimulators, as well as
mitogen-stimulated proliferation assays. In vivo administration
of either syngeneic or allogeneic DIRCs to C57BL/6 recipients
significantly inhibited alloantigen-dependent T cell proliferation
in the respective MLRs in a dose-dependent manner from
37%–91%, when compared to untreated control splenocytes
(Figure 3B, p < 0.001 at 1:1 stimulator to responder ratios,
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Figure 1. Characterization of ABCB5+ Dermal Cell Subpopulations in Human Skin
(A) Representative immunofluorescence staining of ABCB5 protein expression (green) in human skin (left and center left, arrows identify ABCB5+ cells). The
specificity of the anti-ABCB5 staining was assessed using an isotype-matched control antibody (center-right) and by a peptide competition assay (right,
pre-incubation of the ABCB5 antibody with a peptide containing the amino acid sequence of the antibody binding epitope (Frank et al., 2003; Ksander et al.,
2014)). Nuclei are counterstained with DAPI (blue). d, dermis; e, epidermis.
(legend continued on next page)
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respectively). Moreover, in vivo grafting of either recipient-type
or fully MHC-mismatched DIRCs significantly inhibited T cell
proliferation in response to mitogens (p < 0.01, respectively)
(Figure 3C). These findings showed that Abcb5+ DIRCs possess
the capacity to modulate primary immune responses in vivo.
Systematic characterization of the in vivo trafficking pattern of
i.v. grafted Abcb5+ DIRCs, using DiO fluorescent dye-labeled
DIRC tracing by fluorescent microscopy of dissected tissues,
hereby revealed that BALB/c-derived, fully MHC-mismatched
DIRCs can withstand acute immune rejection, with DIRC pres-
ence7days post grafting toC57BL/6 recipients detected in every
recipient tissue examined (range of engraftment frequencies:
2.7 ± 0.8 (muscle) to 37.0 ± 6.3 (thymus) DiO+ DIRCs per 1,000
nucleated tissue cells, mean ± SE, n = 3 mice) (Figure S1).
Intravenous Administration of DIRCs Prolongs Cardiac
Allograft Survival
We next examined the in vivo immunomodulatory effects of
DIRCs on alloimmune responses using a stringent murine het-
erotopic cardiac allotransplantion model (Figure 3A). In a fully
MHC-mismatched strain combination, treatment of C57BL/6
recipients of BALB/c cardiac allografts with donor-type DIRCs
7 days before cardiac transplantation (33 106 cells i.v., n = 8) re-
sulted in significant prolongation of allograft survival compared
to donor-type splenocyte-treated (n = 4, not illustrated) or un-
treated control (n = 4) recipients (Figure 3D, median graft survival
time [MST]: 19 versus 10 versus 7.5 days, p < 0.001, respec-
tively), demonstrating in vivo efficacy of DIRCs to delay graft
rejection. Furthermore, third-party, BALB/c strain DIRCs also
markedly prolonged cardiac allograft survival in C57BL/6
recipients of C3H/HeJ hearts compared to controls (Figure 3D,
MST: 24.5 versus 9 days, p < 0.01, n = 4, respectively), whereas
C57BL/6 recipients of BALB/c cardiac allografts treated with
recipient-strain DIRCs showed only modest prolongation of
cardiac allograft survival (Figure 3D, MST: 10.5 versus
7.5 days, p < 0.05, n = 4, respectively). Thus, prolonged DIRC-
dependent enhancement of cardiac allograft survival requires
DIRC-dependent allogeneic stimulation. To demonstrate that
inhibition of graft rejection is specifically mediated by Abcb5+
dermal cells, we compared the ability of purified Abcb5+ versus
corresponding Abcb5– dermal cells to prolong cardiac allograft
survival. Administration of BALB/c-derived Abcb5+ DIRCs signif-
icantly (p < 0.001) prolonged allograft survival, whereas Abcb5–
dermal cells did not augment survival of BALB/c hearts grafted
to C57BL/6 mice, compared to untreated controls (Figure 3E,
MST: 18.5 (n = 6) versus 6 (n = 5) versus 7 days (n = 11), respec-
tively). Characterization of the tissue distribution pattern of DiO-
labeled BALB/c DIRCs in C57BL/6 recipients of BALB/c hearts
10 days post cardiac allotransplantation (day 17) revealed low
to absent DIRC levels in most tissues examined (Figure S2).
However, as many as 1.9% of nucleated cells were DiO+ DIRCs
in the skin and thymus of recipient mice (Figure S2). Together
with the finding of frequent absence of DIRCs in transplanted
hearts (Figure S2, 0.9 ± 0.7 DIRCs per 1,000 nucleated tissue
cells), our finding of relatively high DIRC frequencies in the
thymus, in addition to native skin, suggests that DIRCs exert their
immunomodulatory effect predominantly systemically, poten-
tially by tolerizing thymic immune cells to alloantigens (also
referred to as central tolerance [Hogquist et al., 2005]), as
opposed to locally, in the cardiac allograft, by interacting with
graft-infiltrating lymphocytes. Characterization of DIRCs with
respect to molecules important for homing to the thymus
(CCR7, E-selectin ligands) and skin (CCR4, CCR10, E-selectin li-
gands) (Sackstein, 2005) revealed expression of all four homing
determinants by the majority of Abcb5+ dermal cells (Figure S3),
consistent with the observed tropism of i.v. administered DIRCs
to thymus and skin.
DIRCs Induce Regulatory T Cells
To examine whether allogeneic DIRCs exert their immunoregula-
tory functions via the induction of tolerogenic immune popula-
tions, we quantified splenic Treg frequencies in DIRC-treated
versus untreated control mice. BALB/c DIRC administration (33
106 cells, i.v.) resulted in increased CD4+CD25+Foxp3+ Treg
numbers in C57BL/6 recipients compared to controls (Figure 3F
and 4.6% ± 0.3% (n = 10) versus 3.1% ± 0.4% (n = 6) mean ±
SE, p < 0.01, day 7 respectively). Consistent with these results
andour findingsofmarkedcardiac allograft prolongation indonor-
and third-party strain DIRC-treated, but not recipient-type DIRC-
treated, allograft recipients compared to controls (Figure 3D),
we found decreased cellular necrosis (Figure S4A) and 3-fold
increased frequencies of intracardiac CD4+Foxp3+ Treg infiltrates
in donor- and third-party strainDIRC-treated versus untreated an-
imals (Figures 3G and S4B, n = 3mice/group, p < 0.0001, respec-
tively). Recipient-typeDIRC administration, on the other hand, did
not result in significant differences in intracardiac Treg numbers
compared to cardiac allografts of untreated controls (Figure 3G,
n = 3 mice, respectively).
(B) Quantification of ABCB5+ cell frequency in human skin determined by immunofluorescence staining, as above, and counting of n = 8–10 independent skin
sections per donor (n = 3).
(C) Immunofluorescence double staining (right panels) of ABCB5 (green) with CD31 or CD34 (red). Nuclei are counterstained with DAPI (blue).
(D) Representative flow cytometry of ABCB5 expression in human skin and representative dual-color flow cytometric analyses examining co-expression of
ABCB5 with the MSC antigens CD29, CD44, CD49e, CD73, CD105 or CD166, the endothelial lineage marker CD31, the stem cell marker CD34, or the
hematopoietic lineage marker CD45.
(E) Representative immunofluorescence double staining of ABCB5 (red) and PD-1 (green) expression (top panels; arrows: ABCB5+PD-1+ cells) and of CD45 (red)
and PD-1 (green) expression (bottom panels; arrows: PD-1+CD45– cells; asterisk: PD-1+CD45+ cell) in human skin specimens, with nuclei counterstained in blue.
(F) Flow cytometry of PD-1 expression by CD45+ versus CD45– cells present in single cell suspension derived from human skin biopsies (left panels: repre-
sentative plots; right panel: mean percentages, n = 4 patients).
(G) PD-1mRNA expression in human patient-derived DIRC short-term cultures (less than passages), as determined byRT-PCR amplification of the full PD-1 CDS.
Human PBMCs were used as a positive control.
(H) PD-1mRNA expression (mean ± SE) determined by real-time PCR in ABCB5+ vs. ABCB5– human skin isolates negative for the pan lymphocyte marker CD45.
(I) Representative flow cytometry plots (left) and mean percentages ±SE (right) of PD-1 protein expression by ABCB5+ vs. ABCB5– human skin cells.
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PD-1 Knockdown Reverses DIRC-Induced Regulatory
T Cell Induction and Attenuates DIRC-Induced
Prolongation of Cardiac Allograft Survival
PD-1-PD-L1 interactions represent a major immune checkpoint
pathway (Francisco et al., 2010), with critical roles in Treg main-
tenance (Francisco et al., 2009; Wang et al., 2008). In order to
investigate whether DIRC-expressed PD-1 is required for the
immunomodulatory capacity of this cell subset, we generated
stable PD-1 knockdown DIRC variants using PD-1 shRNA
lentiviral particles. Significant PD-1 knockdown was shown
both at the mRNA level by using RT-PCR and real-time PCR
(Figure 4A, 60% knockdown) and at the protein level by using
flow cytometric analysis (Figure 4A, >50% knockdown). To
examine whether DIRC-expressed PD-1 has an inhibitory effect
on T cell responses, we i.v. administered 33 106 control shRNA-
transduced versus PD-1 knockdown BALB/c DIRCs to C57BL/6
recipients. Seven days post DIRC injection, we harvested the
spleens of recipient animals and performed standard one-way
MLRs as above (Figures 3B and 3C), using irradiated naive
BALB/c or C3H/HeJ splenocytes as stimulators, or a mitogen-
stimulated proliferation assay. Consistent with our findings using
native DIRCs, in vivo administration of control shRNA-trans-
duced DIRCs significantly inhibited alloantigen-dependent
T cell proliferation in either MLR by >80% and >90% at 1:5
and 1:1 stimulator to responder ratios (p < 0.01), respectively
(Figure 4B). We also found control DIRC transplantation to signif-
icantly (p < 0.001) inhibit ex vivo T cell proliferation in response to
mitogens compared to controls (Figure 4C). Remarkably, DIRC-
specific PD-1 knockdown significantly reversed the inhibitory
effect of control DIRCs on T cell proliferation in both MLRs (p <
0.01, respectively) (Figure 4B and 3.9- and 5.2-fold [BALB/c
MLR] versus 11.4- and 25.7-fold [C3H/HeJ MLR] increase in
proliferation in PD-1 knockdown versus control DIRC treatment
groups at 1:5 and 1:1 stimulator/responder ratios, respectively),
as well as in response to mitogen stimulation (Figure 4C, p <
0.05). Additionally, while control shRNA-transduced BALB/c
DIRC treatment, analogous to native BALB/c DIRCs (Figure 3F),
significantly induced CD4+CD25+Foxp3+ Tregs in C57BL/6
recipient spleens 7 days post i.v. DIRC administration compared
to untreated controls (Figure 4D and 3.4% ± 0.3% (n = 7) versus
1.5% ± 0.2% (n = 9) mean ± SE, p < 0.0001, respectively),
DIRC-specific PD-1 knockdown significantly reversed the Treg
induction observed in control DIRC-treated mice to Treg levels
not significantly different from those in untreated animals
(Figure 4D and 1.7% ± 0.1% (n = 7) versus 1.5% ± 0.2% (n =
9) mean ± SE, NS, respectively). Furthermore, administration
of PD-1-expressing, BALB/c-derived DIRCs to PD-L1(/)
knockout (KO) C57BL/6 mice (Francisco et al., 2009) deficient
in the predominant (Francisco et al., 2010) PD-1 ligand, PD-L1,
did not significantly alter Treg numbers compared to untreated
controls (Figure 4E), indicating a requirement for DIRC-PD-
1:host-PD-L1 interactions for efficient DIRC-dependent Treg
induction. Finally, administration of PD-1 knockdown DIRCs
to C57BL/6 recipients of BALB/c hearts significantly attenu-
ated DIRC-induced prolongation of cardiac allograft survival
compared to control shRNA-transduced DIRCs (Figure 4F,
MST: 10 versus 14 days, p < 0.05, n = 11, respectively), the latter
of which exhibited allograft survival-prolonging effects not signif-
icantly different (p > 0.05) from wild-type DIRCs (Figure 3D).
Together, these results identified a critical in vivo role of DIRC-
expressed PD-1 in Treg induction and prolongation of cardiac
allograft survival and established DIRC-expressed PD-1 as a
previously unrecognized immunoregulatory mechanism.
DISCUSSION
Our study has several important implications. First, identification
of molecularly defined DIRCs has the potential to decisively
advance the field of cell-based immunotherapy, because, thus
far, no molecular marker has been available for the prospective
isolation of comparably potent non-hematopoietic immunoregu-
latory cell subsets with defined mechanism of action from
any adult tissue. Bone marrow (BM)-derived MSCs display
similar molecular profiles such as CD29, CD73, and CD105
expression with negativity for the hematopoietic lineage anti-
gens, CD34 and CD45 (Uccelli et al., 2008), and have previously
been found to suppress T cell proliferation to alloantigens and
mitogens (Bartholomew et al., 2002), evade immunologic rejec-
tion (Devine et al., 2003), regulate Treg function (Casiraghi
et al., 2008), and modulate alloimmune responses in preclinical
animal models (Bartholomew et al., 2002; Casiraghi et al.,
2008). As a result, they have been extensively employed in
cell-based immunomodulatory treatment strategies (Uccelli
et al., 2008). However, unlike ABCB5-purified DIRCs, BM-
MSCs cannot be enriched as pure populations by a single mo-
lecular marker and have thus far failed to consistently prolong
allograft survival in fully MHC-mismatched recipients (Bartholo-
mew et al., 2002; Inoue et al., 2006; Nauta et al., 2006). This
Figure 2. Characterization of Abcb5+ Dermal Cell Subpopulations in Murine Skin
(A) Representative immunofluorescence staining of Abcb5 protein expression (red) in murine skin (left and center). The specificity of the anti-Abcb5 staining was
assessed using an isotype-matched control antibody (right). Arrows in center panel identify Abcb5+ cells. d, dermis; e, epidermis; hf, hair follicle.
(B and C) (B) Representative flow cytometry plots (left) and mean percentages (right) of PD-1 protein expression by Abcb5+ versus Abcb5– murine (BALB/c) skin
cells and (C) representative immunofluorescence double staining of Abcb5 (green) and PD-1 (red) expression (top panels) and of CD45 (green) and PD-1 (red)
expression (bottom panels) in murine skin specimens, with nuclei counterstained in blue. Insets, high magnification.
(D) Immunohistochemical (IHC) analysis of ABCB5 expression across the anastomosis of a human skin to Rag2/mouse xenograft using an anti-ABCB5 mAb
that recognizes both human ABCB5 and murine Abcb5. Isotype-matched negative controls established dermal cell binding of ABCB5 mAb as specific.
(E) Representative IHC images depicting co-expression of ABCB5with humanMHC class I in human skin xenografts, as above. h, human ABCB5+hMHC class I+
cell; m, murine Abcb5+hMHC class I– cell.
(F andG) (F) Representative flow cytometry of surface Abcb5, CD29, CD44, CD49e, CD73, CD105, CD166, CD31, CD34, and CD45 and of (G) PD-1 expression by
early passage murine DIRC cultures.
(H) PD-1 mRNA expression by murine DIRCs as determined by RT-PCR amplification of the full murine PD-1 CDS and
(I) Representative flow cytometry plots (left) and mean percentages (right) of PD-1 protein expression by late passage murine DIRC cultures.
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indicates that immunoregulatory ABCB5+ DIRCs that also ex-
press the immune checkpoint regulator PD-1 might represent
more effective in vivo modulators of allograft rejection. In our
study, i.v. administered DIRCs contained across the various
experiments at least >200,000 Abcb5+PD-1+ cells, a dose
with consistent and reproducible immunomodulatory effects.
Whether lower doses of DIRCs might also be effective, or
whether higher doses or alternative dosing intervalsmight further
enhance the herein documented immunomodulatory effects, de-
serves further investigation. Our results show that the immuno-
regulatory function of ABCB5+ DIRCs is, at least in part, medi-
ated through co-expressed PD-1, because PD-1 knockdown
significantly attenuated DIRC-induced prolongation of cardiac
allograft survival. However, since PD-1 knockdown did not fully
reverse immunosuppressive DIRC function, it is possible that
additional immunoregulatory mechanisms might be operative
in DIRCs that are yet to be elucidated. The potential promise of
molecularly purified DIRCs for use in cell-based immunothera-
peutic strategies is underscored by the additional advantage of
easy accessibility of skin as a tissue source of cell isolation.
Second, our work establishes PD-1 expression by normal tis-
sue-specific non-immune cells and shows that DIRC-expressed
PD-1 functions as a previously unrecognized immunoregulatory
mechanism, similar to our recent demonstration that ABCB5+
skin-associated malignant cells express PD-1 and preferentially
activate Tregs (Schatton et al., 2010). The herein identified role of
DIRC-expressed PD-1 in Treg induction resembles the estab-
lished role of T cellular PD-1 in Treg induction via PD-1:PD-L1
signaling interactions (Francisco et al., 2009; Wang et al.,
2008). Because Tregs represent dominant mediators of immune
homeostasis (Hogquist et al., 2005), including in the skin (Dudda
et al., 2008), our discovery of functional PD-1 expression by
DIRCs supports the existence of a dermal mechanism, in addi-
tion to a previously demonstrated epidermal, Langerhans
cell-mediated mechanism (Seneschal et al., 2012), of Treg main-
tenance in mammalian skin. This finding is of current clinical
relevance also to human cancer, where PD-1 has evolved as a
highly promising target for tumor immunotherapy, with recently
completed clinical trials demonstrating objective response rates
markedly exceeding those achieved with alternative immuno-
therapeutic regimens in patients with advanced disease (Postow
et al., 2015). However, adverse clinical effects of PD-1 antibody
treatment include the occurrence of autoimmune skin condi-
tions, such as vitiligo (Postow et al., 2015). In light of our current
discovery of functional PD-1 expression by immunoregulatory
DIRCs, such autoimmune events could potentially be explained
as a result of off-target inhibition of PD-1 on DIRCs, leading to
dysregulation of DIRC-mediated skin immune homeostasis.
Finally, whereas stem cell populations from the epidermis and
hair follicle have been extensively studied and thoroughly
defined at the molecular level (Fuchs, 2007), additional MSC
phenotype-expressing cell types from the dermis are currently
less well understood. Our result that ABCB5+ DIRCs represents
a dermal cell subset with MSC phenotype warrants examination
whether these cells, like MSCs (Uccelli et al., 2008), might
possess multipotent differentiation plasticity and could therefore
be suitable for evaluation of uses in regenerative medicine,
beyond immunomodulation.
In aggregate, our results identify molecularly defined DIRCs
as a skin-associated immunoregulatory cell population with
promise for cellular immunotherapy applications. Moreover,
they provide initial evidence for a role of non-immune cell-ex-
pressed PD-1 in immunoregulation.
EXPERIMENTAL PROCEDURES
Cell Isolation and Culture Methods
Single cell suspensions from human and murine skin specimens were gener-
ated as described (Schatton et al., 2008) and ABCB5+/Abcb5+ DIRCs isolated
by positive selection as described (Schatton et al., 2008). DIRC cultures were
maintained under previously described culture conditions (Frank et al., 2003).
Flow Cytometry, Immunohistochemistry, and Immunofluorescence
Staining
Analysis of cell-surface marker expression on single cell suspensions was
carried out by flow cytometry as described (Schatton et al., 2008, 2010).
E-selectin ligand stainingwas performedby incubationwith recombinantmouse
E-selectin Fc, as described (Liu et al., 2006). Immunohistochemical or immuno-
fluorescence staining was performed as described (Schatton et al., 2008, 2010).
RT-PCR, Real-Time Quantitative PCR, and Generation of Stable
PD-1 Knockdown DIRCs
Full-length human PD-1 (PDCD1) and murine PD-1 (Pdcd1) were amplified
from human and murine DIRCs, respectively, following reverse transcription
Figure 3. Immunoregulatory Effects of Abcb5+ DIRCs
(A) Diagram depicting the procedure for i.v. DIRC administration (day 0) and (i) abdominal heterotopic cardiac allotransplantation or (ii) spleen cell isolation for
determination of ex vivo T cell proliferation by MLR (day 7). Cardiac allograft survival was (iii) monitored daily by palpation, with rejection defined as the complete
cessation of detectable beating. For evaluation of lymphocytic infiltration and preservation of myocardium by immunohistochemistry, (iv) cardiac allograft were
harvested on day 17.
(B) [3H]thymidine incorporation (mean ± SE) of alloimmune stimulated C57BL/6 splenocytes plotted against increasing stimulator to responder ratios. Stimu-
lators: naive irradiated BALB/c (left) or C3H/HeJ (right) splenocytes. Responders: untreated, C57BL/6 DIRC- or BALB/c DIRC-treated C57BL/6 recipient
splenocytes.
(C) [3H]thymidine uptake (mean ± SE) of mitogen-stimulated splenocytes in experimental groups as in (B).
(D and E) (D) Kaplan-Meier analysis of graft survival in BALB/c DIRC-treated C57BL/6 recipients of BALB/c (left) or C3H/HeJ donor hearts (center), and C57BL/6
DIRC-treated C57BL/6 recipients of BALB/c donor hearts (right), or of (E) Abcb5+ DIRC- versus matched Abcb5– BALB/c-derived dermal cell-treated C57BL/6
recipients of BALB/c donor hearts.
(F) Representative flow cytometry plots (left) and mean percentages (right) of splenic CD4+CD25+Foxp3+ Treg cells in untreated versus BALB/c DIRC-treated
C57BL/6 recipient mice.
(G) Left panel: quantification of Foxp3+ Treg cells in cardiac allografts of untreated, recipient-type-, donor-type-, or third-party strain DIRC-treated C57BL/6
recipients. Bars represent means ± SE of the total number of Foxp3-expressing cells per field of view. Triplicate images for n = 3 mice per group were analyzed.
Right panels: a representative picture of Foxp3 immunohistochemical staining on intracardiac infiltrates for each experimental group is shown.
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of total mRNA using PDCD1/Pdcd1-specific primer pairs. Relative PDCD1/
Pdcd1 transcript levels were determined by real-time quantitative RT-PCR
and calculated using the 2(–DDCt) method as described previously (Frank
et al., 2003; Schatton et al., 2008). Stable PD-1 knockdown DIRCs were gener-
ated using lentiviral transduction particles containing shRNAs against murine
Pdcd1. PD-1 knockdown was confirmed by quantitative RT-PCR and by
flow cytometry.
Mixed Lymphocyte Reaction, Heart Transplantation, In Vivo DIRC
Tracking, and Human Skin Xenotransplantation
C57BL/6 (H2b), BALB/c (H2d), C3H/HeJ (H2k), Rag2/, and PD-L1(/) KO
C57BL/6 mice (Francisco et al., 2009) were maintained and experiments per-
formed under approved protocols in accordance with the Harvard Medical
School Standing Committee on Animals and National Institutes of Animal
Healthcare guidelines. To determine the effect of in vivo DIRC administration
on Treg induction and lymphocyte activation, 3 3 106 DIRCs were injected
i.v. to recipient mice, spleens were harvested 7 days post DIRC, and spleno-
cytes were used for flow cytometric evaluation of Treg frequency or as
responders in standard one-way MLRs as described (Izawa et al., 2010;
Schatton et al., 2010). To determine the effect of i.v. injected DIRCs on murine
cardiac allograft survival, abdominal heterotopic cardiac transplantation was
performed by microsurgery, as described (Izawa et al., 2010), 7 days post
DIRC administration. The in vivo distribution pattern of i.v.-administered
DIRCs was assayed by DiO fluorescent cell labeling and subsequent fluores-
cence microscopy of recipient tissue, as described (Asahara et al., 1997).
Human skin was obtained from discarded surgery specimens in accordance
with the Partners Health Care Research Management Institutional Review
Board and subsequently xenografted onto immunodeficient Rag2/ mice
as described (Juhasz et al., 1993).
Statistics
Statistical differences in allograft survival were assessed as described previ-
ously (Izawa et al., 2010) using Kaplan-Meier graphs and the log-rank test or,
for comparison of median survival, the nonparametric Mann-Whitney test.
Results of cell proliferation (MLRs), flow cytometry, and quantitative PCR
assays were compared statistically using the unpaired Student’s t test or
the nonparametric Mann-Whitney test (comparison of two experimental
groups) or one-way ANOVA followed by the Bonferroni correction (compari-
son of three or more experimental groups) (Izawa et al., 2010; Schatton
et al., 2008, 2010). A two-sided p value <0.05 was considered statistically
significant.
SUPPLEMENTAL INFORMATION
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